<DOC>
	<DOCNO>NCT01324934</DOCNO>
	<brief_summary>The main objective study assessment overall graft rejection rate ( acute , chronic subclinical ) treatment ATG-Fresenius administer addition standard treatment consist CellCept® Myfortic®/TAC without corticosteroid treatment consist CellCept® Myfortic®/TAC corticosteroid first year renal transplantation .</brief_summary>
	<brief_title>Efficacy Safety ATG-Fresenius Following Renal Transplantation , Without Corticosteroids</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Signed date informed consent form , Endstage renal disease , Candidates first transplantation , Retransplant patient eligible graft loss transplantation NOT due immunological reason , Availability heartbeating cadaveric donor 70 year age cold ischemia time shorter 36 hour , Male female patient 18 75 year age inclusive , Patients able comply study related requirement , Patients able receive oral medication , Women childbearing age safe contraceptive method throughout study . Exclusion Criteria Women pregnant breast feeding , Known Human Immunodeficiency Virus , Hepatitis B Virus Hepatitis C Virus infection , Severe actual viral , bacterial fungal infection adequately control , Patients anamnestically know hypersensitivity rabbit immunoglobulin antibody positive rabbit immunoglobulin skin test know allergy component immunosuppressive drug per protocol , Patients high immunological risk define current PRA &gt; 25 % historical PRA &gt; 50 % , Patients receive pretransplant immunosuppressive treatment , include corticosteroid , Patients current history malignancy ( exception basal cell carcinoma squamous cell carcinoma remission ) , Patients previous transplantation except 1st graft loss due surgical complication , Patients receive combined transplantation , Patients major organ dysfunction , Serious psychiatric psychological disorder , Pretransplant thrombocytopenia : &lt; 50,000 thrombocytes/µl , Pretransplant leukopenia : &lt; 2,000 leukocytes/µl , Unable unwilling comply fully protocol , Participation another study investigational medicinal product concurrently within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>acute rejection</keyword>
	<keyword>chronic rejection</keyword>
	<keyword>subclinical rejection</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>steroid-free</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>